BioSpace News Archive

- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced the closing of an underwritten public offering of 3,225,806 shares of its

Third cohort added to independently evaluate the efficacy of NantKwest’s PD-L1 t-haNK natural killer cells plus ImmunityBio’s IL-15 superagonist Anktiva™ (N-803) in third-line or greater therapy for patients with locally advanced or metastatic pancreatic cancer. Two other cohorts for first-line maintenance and second-line randomized against standards of care chemotherapy. 40 patients are currently enrolled in or being evaluated for the Phase 2

Silicon Therapeutics , a privately-held, fully integrated drug design, discovery and development company focused on small molecule therapeutics, today introduced an updated corporate website, which reflects the company’s mission, research approach and core values. The new Silicon Therapeutics site more accurately tells the company’s story and clearly highlights the company’s mission to improve the lives of patients by creati

Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2020 third quarter financial results after the close of the market on Thursday, October 29 th . Natus management will host a conference call the same day beginni

Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2021 financial results at 6:00 am EDT on Wednesday, November 4, 2020 . The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am EDT on November 4 , 2020.

Radius Health, Inc. announced that Peter A. Schwartzman is joining the company as Vice President in the newly formed Capital, Strategy and Transactions Group. Peter, as part of the group, will report to Kelly Martin, CEO of Radius.

Informa Markets announces its complete listing of pharma event dates for 2021 at the opening of the first CPhI Festival of Pharma (05 - 16 October 2020) – the largest ever virtual pharma event.

Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report third quarter 2020 financial results on Thursday, November 5, 2020, after the close of the market. Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call and webcast at 2:00 p.m. PT, 5:00 p.m. ET, on

Hologic, Inc. (Nasdaq: HOLX) announced today that its Aptima® SARS-CoV-2 assay, which initially received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in May, is now authorized for testing of individuals without symptoms or other reasons to suspect COVID-19 infection.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the completion of the manufacturing of the GP2 active ingredient for its planned Phase III clinical trial. After having met all drug specifications and release crite